Influenza vaccine effectiveness in Spain 2013/14: Subtype-specific early estimates using the cycEVA study

Eurosurveillance

Volumn 19, Issue 9, 2014, Pages

  Jimenez Jorge S ^a,b   Pozo, F ^c   de Mateo, S ^a,b   Delgado Sanz, C ^b   Casas, I ^c   Garcaa Cenoz M ^b,d   Castilla, J ^b,d   Sancho, R ^b,e   Etxebarriarteun Aranzabal, L ^f   Quinones, C ^g   Martanez E ^g   Vega, T ^h   Garcia, A ^h   Gimanez J ⁱ   Vanrell, J M ⁱ   Castrillejo, D ^j   Larrauri, A ^a,b  

^a CARLOS III INSTITUTE OF HEALTH   (Spain)

^b CIBER EPIDEMIOLOGÍA Y SALUD PÚBLICA CIBERESP   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

^d INSTITUTO DE SALUD PÚBLICA DE NAVARRA   (Spain)

^e Dirección de Salud Pública y Adicciones de Gipuzkoa   (Spain)

^f Subdirección de Salud Pública y Adicciones de Araba Álava   (Spain)

^g Servicio de Epidemiologia y Prevencion Sanitaria   (Spain)

^h Sanidad de Castilla Y León   (Spain)

ⁱ General de Salud Publica   (Spain)

^j Hospital Comarcal de Melilla   (Spain)

more..

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; VIRUS HEMAGGLUTININ;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DRUG EFFICACY; FEMALE; GENETIC ANALYSIS; HUMAN; INFANT; INFLUENZA A; INFLUENZA VACCINATION; MAJOR CLINICAL STUDY; MALE; PHYLOGENY; PRESCHOOL CHILD; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCHOOL CHILD; SENTINEL SURVEILLANCE; SPAIN; VACCINE PRODUCTION; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; LOGISTIC MODELS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; SPAIN; VACCINATION; YOUNG ADULT;

EID: 84896893676     PISSN: 1025496X     EISSN: 15607917     Source Type: Journal    
DOI: 10.2807/1560-7917.ES2014.19.9.20727     Document Type: Article

References (24)

1. European Centre for Disease Prevention and Control (ECDC). Weekly influenza surveillance overview. 31 January 2014. Main surveillance developments in week 4/2013 (20-26 January 2014). Stockholm: ECDC; 2014. Available from: http://ecdc.europa.eu/en/publications/Publications/influenza-surveillance-overview-31-jan-2014.pdf
2. Savulescu C, Jiménez-Jorge S, de Mateo S, Ledesma J, Pozo F, Casas I, et al. Effectiveness of the 2010/11 seasonal trivalent influenza vaccine in Spain: preliminary results of a case-control study. Euro Surveill. 2011;16(11):pii=19820.
3. Jimenez-Jorge S, de Mateo S, Pozo F, Casas I, Garcia CM, Castilla J, et al. Early estimates of the effectiveness of the 2011/12 influenza vaccine in the population targeted for vaccination in Spain, 25 December 2011 to 19 February 2012. Euro Surveill. 2012;17(12):pii: 20129.
4. Belongia EA, Kieke BA, Donahue JG, Coleman LA, Irving SA, Meece JK, et al. Influenza vaccine effectiveness in Wisconsin during the 2007-08 season: comparison of interim and final results. Vaccine. 2011;29(38):6558-63. http://dx.doi.org/10.1016/j.vaccine.2011.07.002
5. Sullivan SG, Kelly H. Late season interim estimates of influenza vaccine effectiveness reliably predict end of season estimates in Victoria, Australia, 2007 to 2012. Euro Surveill. 2013;18(41):pii=20605. http://dx.doi.org/10.2807/1560-7917.ES2013.18.41.20605
6. European Centre for Disease Control and Prevention (ECDC). WHO Recommendation on influenza virus vaccines for the Northern Hemisphere 2013-2014 season. Stockholm: ECDC; 15 March 2013. Available from:http://www.ecdc.europa.eu/en/activities/sciadvice/_layouts/forms/Review_DispForm.aspx?ID=737&List=a3216f4c-f040-4f51-9f77-a96046dbfd72
7. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the northern hemisphere 2014-15 influenza season and development of candidate vaccine viruses for pandemic preparedness. Geneva: WHO; 2014. Questions and answers. Available from:http://www.who.int/influenza/vaccines/virus/recommendations/201402_qanda_recommendation.pdf
8. Skowronski DM, Chambers C, Sabaiduc S, De Serres G, Dickinson JA, Winter AL, et al. Interim estimates of 2013/14 vaccine effectiveness against influenza A(H1N1)pdm09 from Canada's sentinel surveillance network, January 2014. Euro Surveill. 2014;19(5):pii=20690. http://dx.doi.org/10.2807/1560-7917.ES2014.19.5.20690
9. Flannery B, Thaker SN, Clippard J, Monto AS, Ohmit SE, Zimmerman RK, et al. Interim estimates of 2013-14 seasonal influenza vaccine effectiveness-United States, February 2014. MMWR Morb Mortal Wkly Rep. 2014;63(7):137-42.
10. Castilla J, Martinez-Baz I, Navascues A, Fernandez-Alonso M, Reina G, Guevara M, et al. Vaccine effectiveness in preventing laboratory-confirmed influenza in Navarre, Spain: 2013/14 mid-season analysis. Euro Surveill. 2014;19(6):pii=20700. http://dx.doi.org/10.2807/1560-7917.ES2014.19.6.20700
11. Jiménez-Jorge S, de Mateo S, Delgado-Sanz C, Pozo F, Casas I, Garcia-Cenoz M, et al. Effectiveness of influenza vaccine against laboratory-confirmed influenza, in the late 2011-2012 season in Spain, among population targeted for vaccination. BMC Infect Dis. 2013;13(1):441. http://dx.doi.org/10.1186/1471-2334-13-441
12. Tamura K, Peterson D, Peterson N, Stecher G, Nei M, Kumar S. MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol Biol Evol. 2011;28(10):2731-9. http://dx.doi.org/10.1093/molbev/msr121
13. The GISAID Initiative. GISAID. Available from: http://www.gisaid.com/
14. Instituto de Salud Carlos III. Informes anuales y semanales de Vigilancia de la Gripe en Espa-a. Sistema de Vigilancia de la Gripe en Espa-a. [Annual and weekly national influenza reports. Spanish Influenza Surveillance System]. Madrid: Centro Nacional de Epidemiología Instituto de Salud Carlos III; 2012. [Accessed 15 January 2014]. Spanish. Available from: http://www.isciii.es/cne-gripe-infsemanal
15. European Centre for Disease Prevention and Control (ECDC). Influenza virus characterisation. Summary Europe December 2013. Stockholm: ECDC; 2014. p. 1. Available from:http://www.ecdc.europa.eu/en/publications/Publications/influenza-virus-characterisation-dec-2013.pdf
16. o 379. Comienza la fase de descenso de la onda epidémica 2013/14 en Espa-a, una vez sobrepasado el pico máximo de incidencia de gripe. Sistema de Vigilancia de la Gripe en Espa-a. [Influenza activity is decreasing in Spain after reaching the 2013/14 influenza epidemic peak]. Madrid: Instituto de Salud Carlos III; 2014. Spanish. Available from:http://vgripe.isciii.es/gripe/documentos/20132014/boletines/grn052014.pdf
17. Kissling E, Valenciano M. Early estimates of seasonal influenza vaccine effectiveness in Europe, 2010/11: I-MOVE, a multicentre case-control study. Euro Surveill. 2011;16(11):pii=19818.
18. Jiménez-Jorge S, Savulescu C, Pozo F, de Mateo S, Casas I, Ledesma J, et al. Effectiveness of the 2010-11 seasonal trivalent influenza vaccine in Spain: cycEVA study. Vaccine. 2012;30(24):3595-602. http://dx.doi.org/10.1016/j.vaccine.2012.03.048
19. Skowronski DM, Janjua NZ, Sabaiduc S, De Serres G, Winter AL, Gubbay JB, et al. Influenza A/subtype and B/lineage effectiveness estimates for the 2011-12 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis. 2014; Jan 19. [Epub ahead of print]. http://dx.doi.org/10.1093/infdis/jiu048
20. Savulescu C, Jiménez-Jorge S, De Mateo S, Pozo F, Casas I, Perez-Bre-a P, et al. Using surveillance data to estimate pandemic vaccine effectiveness against laboratory confirmed influenza A(H1N1)2009 infection: two case control studies, Spain, season 2009-2010. BMC Public Health. 2011;11:899. http://dx.doi.org/10.1186/1471-2458-11-899
21. Fielding JE, Grant KA, Papadakis G, Kelly HA. Estimation of type-and subtype-specific influenza vaccine effectiveness in Victoria, Australia using a test negative case control method, 2007-2008. BMC Infect Dis. 2011;11:170. http://dx.doi.org/10.1186/1471-2334-11-170
22. Belongia EA, Kieke BA, Donahue JG, Greenlee RT, Balish A, Foust A, et al. Effectiveness of inactivated influenza vaccines varied substantially with antigenic match from the 2004-2005 season to the 2006-2007 season. J Infect Dis. 2009;199(2):159-67. http://dx.doi.org/10.1086/595861
23. Kissling E, Valenciano M, Larrauri A, Oroszi B, Cohen JM, Nunes B, et al. Low and decreasing vaccine effectiveness against influenza A(H3) in 2011/12 among vaccination target groups in Europe: results from the I-MOVE multicentre case-control study. Euro Surveill. 2013;18(5):pii=20390.
24. World Health Organization (WHO). Recommended composition of influenza virus vaccines for use in the 2014-2015 northern hemisphere influenza season. Geneva: WHO; 20 February 2014. Available from:http://www.who.int/influenza/vaccines/virus/recommendations/2014_15_north/en/